(Q34610608)

3 August 2017

1 reference

title

Pathophysiology and treatment of psychosis in Parkinson's disease: a review (English)

1 reference

3 August 2017

1 reference

1 reference

1 reference

2

Hubert H Fernandez

1 reference

3 August 2017

1

Laura Beth Zahodne

1 reference

3 August 2017

publication date

1 January 2008

1 reference

3 August 2017

1 reference

3 August 2017

volume

25

1 reference

3 August 2017

issue

8

1 reference

3 August 2017

page(s)

665-682

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-200825080-00004

3 August 2017

exact match

0 references

cites work

Subthalamic nucleus deep brain stimulation in elderly patients--analysis of outcome and complications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Preliminary FMRI evidence of visual system dysfunction in Parkinson's disease patients with visual hallucinations

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Visual hallucinations in Parkinson's disease: clues to separate origins

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Chronic deep brain stimulation of the subthalamic nucleus for Parkinson's disease: effects on cognition, mood, anxiety and personality traits

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Schizophrenia, antipsychotic drugs, and cardiovascular disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? A cautious or cautionary tale?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Psychosis in Parkinson's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Schizophrenia, the metabolic syndrome and diabetes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

The art of treating Parkinson disease in the older patient.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Treatment of psychosis in Parkinson's disease: safety considerations

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Biological perspectives. Aripiprazole: a third generation of antipsychotics begins?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Clozapine in Parkinson's disease psychosis: 5-year follow-up review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Donepezil in the treatment of hallucinations and delusions in Parkinson's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Intrinsic and extrinsic psychosis in Parkinson's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Management of psychosis in Parkinson's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Sleep disorders in patients with Parkinson's disease: epidemiology and management

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Prospective study of hallucinations and delusions in Parkinson's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Serotonin and amino acids: partners in delirium pathophysiology?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Acetylcholine in mind: a neurotransmitter correlate of consciousness?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Early dopaminergic drug-induced hallucinations in parkinsonian patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Parkinson's Study Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

A study of visual hallucinations in patients with Parkinson's disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Dopaminergic sensitization: implications for the pathogenesis of schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Visual hallucinations associated with Parkinson disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Cholinesterase inhibition in Parkinson's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Psychoeducation in first-episode psychosis: a therapeutic process

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Parkinson's disease: drug-induced psychiatric states.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Neuroleptic sensitivity to risperidone in Lewy body dementia.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Risperidone for hallucinations in levodopa-treated Parkinson's disease patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson's disease and Alzheimer's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

The Management of the Levodopa Psychoses

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Exacerbation of parkinsonism by tacrine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Levodopa-induced psychosis: a kindling phenomenon

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Visual Hallucinations and Delirium During Treatment with Amantadine (Symmetrel)

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.

7 July 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200825080-00004

Risk factors for nursing home placement in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200825080-00004

Psychiatric comorbidities in patients with Parkinson disease and psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200825080-00004

Altered cortical visual processing in PD with hallucinations: an fMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200825080-00004

Parkinson's disease and sleepiness: an integral part of PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200825080-00004

Prospective longitudinal assessment of hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200825080-00004

Longitudinal outcome of Parkinson's disease patients with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200825080-00004

The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200825080-00004

Phenotypic associations of tau and ApoE in Parkinson's disease.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Hallucinations in Parkinson disease in the prelevodopa era.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson's disease.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Aripiprazole in psychosis associated with Parkinson's disease

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Ziprasidone in the treatment of Parkinson's disease psychosis

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Quetiapine for insomnia in Parkinson disease: results from an open-label trial

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Best clinical practice with ziprasidone: update after one year of experience

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Use of ziprasidone in parkinsonian patients with psychosis.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Association between family history of dementia and hallucinations in Parkinson disease.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Factors associated with drug-induced visual hallucinations in Parkinson's disease

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Threatening auditory hallucinations and Cotard syndrome in Parkinson disease

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Diabetes mellitus among parkinsonian patients treated chronically with clozapine

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Hallucinations in Parkinson's disease: a follow-up study.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Ziprasidone in Parkinson's disease psychosis

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Aripiprazole and Parkinson's disease psychosis

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Retinal involvement in dementia with Lewy bodies: a clue to hallucinations?

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Short-term effect of bilateral subthalamic stimulation for advanced Parkinson's disease.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Long‐term outcome of quetiapine use for psychosis among parkinsonian patients

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Reality monitoring and visual hallucinations in Parkinson's disease.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Olanzapine treatment for dopaminergic-induced hallucinations

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Factors impacting on quality of life in Parkinson's disease: results from an international survey.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Auditory hallucinations in Parkinson's disease

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Dopaminergic hallucinosis with fluoxetine in Parkinson's disease

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Serotonergically active agents in levodopa-induced psychiatric toxicity reactions.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Mental disorders in Parkinson's disease after treatment with L-DOPA.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045853

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease

26 October 2018

1 reference

12 December 2020

Poor visual discrimination and visual hallucinations in Parkinson's disease

1 reference

12 December 2020

Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis

1 reference

12 December 2020

1 reference

12 December 2020

Risperidone in Parkinson's disease

1 reference

12 December 2020

Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy

1 reference

12 December 2020

Effectiveness of cognitive therapy with coping training for persistent auditory hallucinations: a retrospective study of attenders of a psychiatric out-patient department

1 reference

12 December 2020

Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine

1 reference

12 December 2020

The malignant course of "benign hallucinations" in Parkinson disease

1 reference

12 December 2020

1 reference

12 December 2020

Ondansetron for hallucinosis in advanced Parkinson's disease

1 reference

12 December 2020

Serum prolactin, leptin, lipids and lipoproteins levels during antipsychotics treatment in Parkinson's disease and related psychosis

1 reference

12 December 2020

Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments

1 reference

12 December 2020

Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone

1 reference

12 December 2020

1 reference

12 December 2020

Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial

1 reference

12 December 2020

Pharmacology of hallucinations induced by long-term drug therapy

1 reference

12 December 2020

Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations

1 reference

12 December 2020

Risperidone for psychotic and behavioural symptoms in Lewy body dementia

1 reference

12 December 2020

Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group

1 reference

12 December 2020

1 reference

12 December 2020

Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease

1 reference

12 December 2020

Coping strategies for visual hallucinations in Parkinson's disease

1 reference

12 December 2020

ASHP therapeutic position statement on the use of second-generation antipsychotic medications in the treatment of adults with psychotic disorders

1 reference

12 December 2020

Aripiprazole associated with severe exacerbation of Parkinson's disease

1 reference

12 December 2020

Nonmotor fluctuations in Parkinson's disease: frequent and disabling

1 reference

12 December 2020

Ondansetron treatment of L-dopa-induced psychosis

1 reference

12 December 2020

Relationship between age and subtypes of psychotic symptoms in Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease.

1 reference

12 December 2020

Clozapine and risperidone treatment of psychosis in Parkinson's disease

1 reference

12 December 2020

10.2165/00002512-200825080-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference